# Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

> **NCT04811131** · PHASE2 · TERMINATED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 114 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** ARQ-252 cream 0.3%
- **DRUG:** ARQ-252 Vehicle cream
- **DEVICE:** NB-UVB phototherapy active treatment
- **DEVICE:** NB-UVB phototherapy sham treatment

## Key facts

- **NCT ID:** NCT04811131
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-04
- **Primary completion:** 2021-08-09
- **Final completion:** 2021-08-09
- **Target enrollment:** 114 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811131, "Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04811131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*